Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072111 · ClinicalTrials.gov registry record · Phase 1
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00072111 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state.
The verdict
NCT00072111, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Biological therapies, such as anakinra, may interfere with the growth of the tumor cells and slow the growth of metastatic tumors that express the interleukin-1 gene. PURPOSE: This phase I trial is studying the side effects and best dose of anakinra in treating patients with metastatic cancer that expresses the interleukin-1 gene.
Conditions Studied
Interventions
- BIOLOGICAL anakinra
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072111
The ClinicalTrials.gov registry entry for NCT00072111 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which anakinra is the first listed.
NCT00072111 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00072111 about?
NCT00072111 is a clinical study titled "Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene". RATIONALE: Biological therapies, such as anakinra, may interfere with the growth of the tumor cells and slow the growth of metastatic tumors that express the interleukin-1 gene. PURPOSE: This phase I trial is studying the side effects and best dose of anakinra in treating patients with metastatic c...
What is the current status of trial NCT00072111?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-09.
What conditions does trial NCT00072111 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00072111?
The interventions under investigation include: anakinra (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072111?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072111 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.